FDA Approvals of Binimetinib in Combination with Encorafenib: Advancements in Targeted Therapy for Metastatic Melanoma and Non-Small Cell Lung Cancer with BRAF V600E Mutation
In a significant stride towards combating metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, the FDA has granted approval for the use of binimetinib in combination with encorafenib.